Biopharmaceutical business Dimerix (ASX:DXB) should see boosted recruitment rates in the UK for its trial of focal segmental glomerulosclerosis (FSGS) after it entered a collaboration with the largest rare kidney disease registry in the world, the UK's National Registry of Rare Kidney Diseases (RaDaR), according to a research note from Euroz Hartleys.

RaDaR has more than 34,500 rare kidney disease patients recruited from 109 hospitals in the UK, with plans to identify patients suitable for Phase 3 of Dimerix's trial, the note stated.

Euroz Hartleys maintained its speculative buy rating and AU$0.91 price target on Dimerix.